Vinorelbine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Treatment and Liver Dysfunction

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed advanced solid tumor
• * Any histology allowed
• Refractory to standard therapy OR no standard therapy exists
• * Previously untreated non-small cell lung cancer allowed, provided abnormal liver function is present, defined as moderate (group 3) or severe (group 4)
• Measurable disease not required
• * Present measurable disease requires baseline measurements within 4 weeks of study entry
• Patients with acute hepatitis from viral or drug etiologies should recover to a stable baseline prior to study therapy
• History of brain metastasis allowed, provided the following criteria are met:
• * Metastasis has been controlled by radiotherapy or surgery
• * Patient is not currently on corticosteroids
• * Neurologic status is stable
• PATIENT CHARACTERISTICS:
• Karnofsky performance status 70-100%
• Life expectancy ≥ 2 months
• ANC = 1,500/mm³
• Platelet count = 100,000/mm³
• Hemoglobin = 10 g/dL (transfusion to this level allowed)
• Creatinine \< 1.5 mg/dL OR creatinine clearance \> 60 mL/ min
• Patients with EKG evidence of first- or second-degree AV block or left or right bundle branch block are ineligible for the lidocaine bolus, but may otherwise be treated on this protocol
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• No concurrent illness (e.g., cardiovascular, pulmonary, or central nervous system) that is poorly controlled or of such severity that the investigator deems unwise to enter the patient on protocol
• Must have ability to comply with study treatment and required tests
• Obstructive jaundice requires a drainage procedure prior to study treatment
• PRIOR CONCURRENT THERAPY:
• See Disease Characteristics
• Recovered from prior therapy
• At least 3 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosourea therapy)
• No prior radiotherapy to \> 30% of the bone marrow or more than standard adjuvant pelvic radiotherapy for rectal cancer